Calcan is primarily used for managing essential hypertension, which is a condition involving chronic elevation of blood pressure readings. The medicine is commonly used to help with the symptom cluster of elevated vascular strain, where resistance in the peripheral arteries creates noticeable physiological strain. It is generally used to help address the core condition of essential hypertension, which may present as mild-to-moderate or severe elevation, and is applied across domains where additional symptomatic support is needed.

It is relevant when supportive symptom management is appropriate for patients managing a long-term condition. Maintaining stable blood pressure control is generally used in areas where short-term symptom management is appropriate to support long-term cardiovascular health. The treatment is relevant in clinical scenarios requiring continuous, stable management of chronic hypertension, where it plays a role in managing the symptom cluster of increased peripheral resistance. This approach contributes to easing the overall symptom load and assists with maintaining functional stability. Beyond blood pressure reduction, Calcan’s therapeutic benefit includes providing protective support for vital organs, which is particularly relevant in patient groups with co-existing conditions like diabetes.

---

Quick Fact: Support for Elevated Vascular Strain

Calcan is commonly used to help manage symptoms related to systemic imbalance that arise from high blood pressure, and is relevant for easing the strain on the heart and kidneys.

Calcan (Lercanidipine hydrochloride) is officially designated for use in adults aged 18 years and older who are managing essential hypertension. Regulatory documentation establishes clear restrictions and prohibitions on who must not use the medicine.

Status	Population or Condition
Contraindicated	Severe hepatic or severe renal impairment (GFR <30 ml/min); Pregnancy and lactation; Hypersensitivity to Lercanidipine or any dihydropyridine; Untreated congestive heart failure; Unstable angina pectoris; Myocardial infarction within the last month; Left ventricular outflow tract obstruction; Co-administration with strong CYP3A4 inhibitors or grapefruit juice.
Not Recommended	Children and adolescents under 18 years of age (safety and efficacy have not been established).
Use with Caution	Older adults (special care advised when starting therapy); Patients with mild to moderate renal or hepatic dysfunction; Patients with sick sinus syndrome (if no pacemaker is fitted).

The official eligibility profile is strictly defined by these regulatory classifications. Eligibility is restricted to populations without severe organ impairment or acute cardiac instability, as explicitly mandated in authoritative government prescribing labels.

Interactions with other medicines and products

Category	Interacting Substances/Conditions	Regulatory Status
Absolute Contraindications	Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir), Cyclosporin, Grapefruit/Grapefruit Juice	Co-administration is formally prohibited.
Metabolic Interactions	CYP3A4 Inducers (e.g., Phenytoin, Rifampicin)	Risk of reduced Calcan plasma levels and efficacy.
Pharmacodynamic Effects	Alcohol, Other Antihypertensives	May potentiate the vasodilating antihypertensive effect.
Timing Requirement	Food (High-Fat Meal)	Mandatory administration separation: must be taken at least 15 minutes before a meal.

The interaction profile for Calcan is characterized by its dependence on the CYP3A4 metabolic pathway, which dictates the strict prohibitions. Co-administration of strong inhibitors of this enzyme, such as certain antifungal and antiviral medicines, results in a substantial pharmacokinetic increase in Calcan exposure (e.g., an 8-fold increase in Cmax). The immunosuppressant Cyclosporin is also prohibited due to significant increases in plasma levels of both substances.

Other documented pharmacokinetic interactions include co-administration with Metoprolol, which reduces Calcan's bioavailability by 50%, and Calcan's effect on Simvastatin, increasing its exposure by 56%—a risk managed by required administration time separation. In specific populations, the antihypertensive effect may be enhanced in patients with mild to moderate hepatic impairment.

How Calcan Works

Targeted Blockade of Vascular Calcium Channels

Calcan's active ingredient, Lercanidipine, engages a mechanism that is highly specific to the L-type voltage-gated calcium channel ( Ca v1.2) found on the surface of vascular smooth muscle cells. By physically inhibiting the channel, the drug prevents the necessary influx of extracellular calcium ions ( Ca^2+), which is a necessary molecular step for muscle contraction. This action influences the signaling cascade that results in the widening of peripheral arteries.

Disruption of Smooth Muscle Contraction Cascade

The suppression of intracellular Ca^2+ levels disrupts the excitation-contraction coupling pathway. This prevents the activation of key enzymes like Myosin Light Chain Kinase ( MLCK), consequently inhibiting the formation of the actin-myosin cross-bridge. The resulting cellular state is one of muscle relaxation and widespread vasodilation, which is the physiological consequence of this mechanism.

Reduction of Systemic Vascular Resistance ( TPR)

The cumulative relaxation of numerous small peripheral arteries reduces the overall Total Peripheral Resistance ( TPR) within the circulatory system. This systemic change directly lowers the afterload—the resistance the heart must overcome to pump blood—thereby providing the physiological means by which arterial pressure is reduced.

Administration Guidelines for Calcan

Calcan is an oral film-coated tablet containing Lercanidipine hydrochloride, available in 10 mg and 20 mg strengths. Usage follows a specific regimen of timing, dosage, and population-specific considerations.

Standard Dosing and Timing

The established route of administration is oral, with a standard dosing frequency of once daily. The usual starting dose for adults is 10 mg daily, which may be increased to a maximum daily dose of 20 mg based on individual response. The medication is typically taken at least 15 minutes before a meal, preferably in the morning, as food can alter its absorption. It is also established that Calcan should not be taken with grapefruit or grapefruit juice.

Procedural and Adjustment Rules

The tablet should be swallowed whole with water. The score line found on the tablet is solely to assist with swallowing and is not intended for dividing the dose into halves. Dose increases are generally gradual, as the full effect may not be apparent until approximately two weeks of consistent use.

Population-Specific Instructions

For older adults, no routine daily dose adjustment is specified, though treatment initiation is approached with caution. For patients with mild-to-moderate renal or hepatic impairment, caution is observed, and any increase to the 20 mg daily dose is undertaken carefully. Calcan is not recommended for use in patients with severe hepatic or severe renal impairment (GFR < 30 ml/min), and its use is not established in the pediatric population (under 18 years of age).

Research evidence / Overview of Studies for Calcan

Evidence for Use in Essential Hypertension

The core evidence primarily comes from short-term Randomized Controlled Trials (RCTs) and controlled comparative studies. These studies were often synthesized in meta-analyses and applied in research contexts involving fluctuating or unstable symptoms. Research focused on surrogate endpoints, meaning studies examined change from baseline in measurements like seated Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) over periods typically lasting 4 to 12 weeks. These outcomes monitoring physiological strain or stress provided context on how blood pressure evolved in the observed adult populations.

Studies monitored whether patients reached pre-defined blood pressure goals. Research highlights changes measured during the study period where Calcan was observed alongside changes in both SBP and DBP in the observed populations. While research describing the short-term physiological strain exists, there is limited information for long-term outcomes. The majority of the high-quality data is from studies with limited follow-up durations—only a few months. Long-term effects, particularly regarding the monitoring of major cardiovascular events like heart attack or stroke, are not fully established by dedicated Calcan trials.

---

Evidence for Use in Specific Groups and Combination Therapy

Research has explored Calcan’s patterns in certain specific populations, including older adults and those with co-existing Type 2 Diabetes Mellitus. Studies in these groups measured not only blood pressure changes but also outcomes related to systemic or functional imbalance, such as renal-related outcomes like changes in microalbuminuria. For patients with severe or resistant hypertension, Calcan was evaluated in clinical trials as an add-on treatment alongside other antihypertensive drugs, and these studies monitored whether the combination treatment was associated with patients reaching target blood pressure goals.

---

Evidence Gaps and Areas Requiring Further Study

Official regulatory and scientific literature identifies several areas where the research concerning Calcan remains uncertain or data are still emerging. The research record is generally insufficient to characterize Calcan's use, effect patterns, or appropriate application in children and adolescents (under 18 years of age). Data for patients with severe impairment of the liver or kidneys are still emerging. Subgroup findings concerning specific, high-risk cardiac groups—such as patients with certain forms of congestive heart failure—data are still emerging, and research provides context but not individual predictions.

Common questions about Calcan (FAQ)

Q: How long does the effect of one Calcan dose usually last?

Calcan is designed as a long-acting medicine that is formulated to support the once-daily administration schedule. This approach indicates its physiological effects are sustained over a typical 24-hour period, according to regulatory prescribing information.

---

Q: Why is Calcan sometimes called a 'selective modulator'?

Calcan is officially classified as a Dihydropyridine Calcium Channel Blocker (CCB). The term 'selective' refers to the drug’s highly targeted action on the blood vessels, meaning it primarily affects the vascular smooth muscle cells to cause vasodilation (widening of the arteries).

---

Q: What if I take supplements, like vitamins or herbs, with Calcan?

Herbal products like St. John's Wort (Hypericum perforatum) can interact with Calcan by potentially reducing its effectiveness. Official guidance indicates that healthcare providers should be informed about all supplements and herbs being used, as some may affect the drug's activity via the liver enzyme CYP3A4.

---

Q: How does the drug Calcan leave the body?

Calcan is extensively broken down, or metabolized, by a specific enzyme in the liver called CYP3A4. After being metabolized, the drug and its components are eliminated from the body primarily through both the urine and the feces.

---

Q: Do clinical trials of Calcan include diverse patient groups?

Clinical studies for Calcan have included specific patient populations beyond the general adult group with high blood pressure. Official documents mention research involving older adults and those with co-existing conditions, such as Type 2 Diabetes Mellitus, to understand its effects in these groups.

---

Q: What is the chance of having a serious side effect from Calcan?

Serious side effects, such as a severe allergic reaction or an increase in the frequency of angina attacks, are rare or very rare. Official product information classifies these types of events as affecting up to 1 in 1,000 people or even less.

---

Q: Is Calcan known to cause weight gain?

Official prescribing information does not list weight gain as a common, uncommon, or rare side effect. If you experience unexpected changes in weight, seeking advice from a healthcare professional is appropriate.

---

Q: What happens if a dose of Calcan is missed?

Regulatory information describes the process as skipping the forgotten dose entirely and taking the next one at the usual time. Official sources indicate that a double dose should not be taken to compensate for the one that was missed.

---

Q: Does Calcan cause any problems with sleep?

Sleepiness (somnolence) is listed as a rare side effect in official reports, meaning it may affect up to 1 in 1,000 people. Insomnia (difficulty sleeping) is also sometimes reported as a rare side effect in official information.

---

Q: Can Calcan affect blood sugar levels?

Clinical data suggests that Calcan is not generally associated with negative changes to blood sugar levels (glucose homeostasis). This finding provides context for its use in patients who are managing blood pressure alongside conditions that affect blood sugar.

---

Q: Is Calcan a controlled substance?

Calcan is classified as a prescription-only medicine (POM) but is not designated as a controlled substance in major regulatory regions. This means it requires a prescription from a doctor but is not subject to the strict handling and tracking rules of controlled drugs.

---

Q: Is it true that Calcan requires special monitoring or lab tests?

Regulatory documents state that patients with pre-existing mild-to-moderate liver or kidney impairment necessitate caution and potential monitoring. Changes in liver function, detectable by blood tests, have also been reported in very rare cases.

---

Q: What is the purpose of the black box warning (if any) associated with Calcan?

Calcan is not associated with a Black Box Warning. The Black Box Warning is the strongest warning required by the FDA on prescribing information for drugs that carry significant or potentially fatal risks.

---

Q: Does Calcan have a risk of dependence or withdrawal symptoms?

Official information does not suggest that Calcan is addictive or causes dependence. However, stopping the drug without medical supervision is associated with a potential for elevated blood pressure, which may increase the risk of serious cardiovascular events.

---

Q: Can Calcan affect mood or cause anxiety?

Official prescribing information indicates that anxiety is sometimes reported as a rare side effect of Calcan, potentially affecting up to 1 in 10,000 users. Other mood changes are not commonly reported in regulatory documents.

---

Q: What should be done if someone accidentally takes too much Calcan?

In the event of an overdose, immediate medical attention should be sought. An overdose can cause a significant drop in blood pressure, leading to symptoms like dizziness or fainting, and may result in an irregular or faster heartbeat.

---

Q: Is Calcan gluten-free or suitable for people with common allergies?

Calcan tablets contain lactose, which makes them unsuitable for people with rare hereditary problems like galactose intolerance. The patient information leaflet contains a full list of inactive ingredients (excipients) that can be checked for specific sensitivities.

---

Q: What if I forget to take Calcan for a few days?

If several doses are missed, you should skip all the forgotten doses and resume taking your next dose at the regular time. Consultation with the prescribing doctor is appropriate for guidance on resuming therapy, as blood pressure control may be affected.

---

Q: Are there known drug interactions with birth control pills and Calcan?

Due to limited clinical data, official documentation includes a recommendation for women of child-bearing potential to use effective contraception while on Calcan. This is related to the fact that Calcan is metabolized by the CYP3A4 enzyme, which also affects the metabolism of many other drugs.

The official regulatory documentation for Calcan (Lercanidipine hydrochloride tablets) details specific conditions required for storage and safe disposal.

Storage Conditions

Calcan must be stored at a temperature not exceeding 25 C. To maintain product stability, the tablets must be kept in the original package to protect from moisture and light.

For child safety, the medicine must be stored out of the sight and reach of children. Use of the product is prohibited after the expiry date (EXP) stated on the carton.

Disposal Instructions

Unused or expired Calcan must not be thrown away via wastewater or household waste. Disposal must be carried out in accordance with local requirements, and patients should consult a pharmacist for guidance on proper pharmaceutical waste disposal.